



Recent Progress of Nanomedicine and Targeted Drug Delivery for Cancer Treatment 2.0

Guest Editors:

Dr. Huijie Zhang

School of Life Sciences and
Health Engineering, Jiangnan
University, Wuxi, China

Dr. Shini Feng

School of Life Sciences, Shanghai
University, Shanghai, China

Deadline for manuscript
submissions:

25 August 2024

Message from the Guest Editors

Dear Colleagues,

Cancer is the second leading cause of death worldwide and is the most complex and challenging disease known to mankind. Effective cancer treatment is still a great challenge due to the complex underlying mechanisms of tumorigenesis and tumor metastasis, as well as the intrinsic limitations of conventional cancer therapies. There is an urgent need for the discovery of novel therapeutic strategies with superior anticancer capabilities. In recent years, nano-drug delivery systems have been extensively investigated and applied as alternatives to conventional cancer treatments. Cancer nanomedicines aim at the targeted delivery of chemotherapeutic drugs to the tumor site, and utilize strategies such as passive targeting, active targeting, and stimuli-triggered drug release, while simultaneously decreasing drug accumulation in normal tissues; together, they lead to improved therapeutic efficacy and reduced side effects.

This Special Issue will highlight recent progress in the development of novel nanomedicines and targeted drug delivery systems for cancer therapy. All original Articles or comprehensive Reviews will be welcomed.

Dr. Huijie Zhang
Dr. Shini Feng
Guest Editor



mdpi.com/si/166929

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com